16:32:11 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-21 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-07-03 Ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2021-07-21 08:30:00
  • After completion of successful verification audit by its notified body DEKRA, IRRAS' Medical Device Single Audit Program (MDSAP) certification has been extended for three years until July 2024
  • The company's MDSAP/ISO 13485:2016 certification will also have a scope upgrade to include company's new manufacturing facility following the audit's site inspection
  • The expanded ISO certification now allows product manufactured in IRRAS' new facility to be shipped globally

Stockholm, July 21, 2021 - IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced today that it has successfully completed an in-person verification audit of its Quality Management System (QMS) by DEKRA, the company's notified body.  Earlier this year, IRRAS announced that the company had received certification of its QMS under the Medical Device Single Audit Program (MDSAP).  As a result of this verification audit, the company's MDSAP certification that covers both its IRRAflow and Hummingbird ICP Monitoring product lines will now be extended for two additional years and will remain valid until July 2024. 

This DEKRA audit also included a thorough inspection and validation of IRRAS' new manufacturing facility, IRRAS South, Inc.  After this successful audit, IRRAS' corporate ISO 13485:2016 certification will be expanded to also cover this facility, which has now been audited with no major findings by both the United States Food and Drug Administration (FDA) and DEKRA, IRRAS' European regulatory representative.  IRRAS can now manufacture and globally ship medical devices from this facility based on these positive audit outcomes.

MDSAP is a stringent audit process that was established to enable medical device manufacturers to undergo one single audit of their QMS that covers the requirements of participating regulatory jurisdictions in Australia (TGA), Brazil (ANVISA), Canada (Health Canada), Japan(MHLW) and the United States (FDA).  This extended MDSAP certification will support IRRAS' efforts to secure product regulatory clearance in these new markets.

"This recently completed audit is another strong confirmation of the meaningful progress made by our IRRAS team," said Will Martin, President and CEO of IRRAS.  "Not only does the extension of our MDSAP certificate allow us to pursue meaningful regulatory approvals over the next three years, but it is an important milestone to receive ISO certification for IRRAS' first in-house manufacturing facility.  This accomplishment validates our team's collective commitment to quality and also secures necessary supply of IRRAflow capital equipment for our growing number of customers around the globe."

About IRRAS
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

 

For more information, please contact:

Sten Gustafsson
Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on July 21, 2021 at 08:30 (CET).